{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:12:51Z","timestamp":1782832371433,"version":"3.54.5"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The programmed cell death protein 1 inhibitor pembrolizumab, an immune checkpoint inhibitor, has subsequently been approved for the treatment of a wide variety of malignant tumors. Compared with conventional chemotherapy, immunotherapy is associated with a unique set of immune reactions, known collectively as immune-related adverse events. Although often mild, dermatologic toxicity can occasionally be high grade and potentially life-threatening. Here we describe a rare case of bullous pemphigoid (BP) associated with pembrolizumab. A 79-year-old male patient presented with scattered erythema, papules, blisters, and pruritus after pembrolizumab treatment. Then, the rash gradually aggravated and spread to the whole body. The extensive edematous erythema, blisters, bullae, and blood blisters were loose and easy to rupture, forming an erosive surface and with pruritus and obvious pain. The hemidesmosomal protein BP180 (type XVII collagen) was detectable in the serum, and the histological examination diagnosis was bullous pemphigoid. After 10 days of glucocorticoid (methylprednisolone, iv, 80 mg\/day) treatment, new blister formation ceased. We need to increase the awareness on and facilitate the earlier identification of the cutaneous adverse effects of BP with immunotherapy so that treat can begin early in order to limit the duration and severity of toxicity.<\/jats:p>","DOI":"10.3389\/fimmu.2021.731774","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T10:17:58Z","timestamp":1631614678000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiaoyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjiang","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical Features, Predictive Correlates, and Pathophysiology of Immune-Related Adverse Events in Immune Checkpoint Inhibitor Treatments in Cancer: A Short Review","volume":"6","author":"Yoest","year":"2017","journal-title":"Immunotarg Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1634\/theoncologist.2016-0164","article-title":"Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer","volume":"22","author":"Okane","year":"2017","journal-title":"Oncologist"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive Meta-Analysis of Key Immune-Related Adverse Events From CTLA-4 and PD-1\/PDL1 Inhibitors in Cancer Patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv182","article-title":"A Systematic Review of Immune-Related Adverse Event Reporting in Clinical Trials of Immune Checkpoint Inhibitors","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A Review of Cancer Immunotherapy Toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of Immune Checkpoint Blockade Dysimmune Toxicities: A Collaborative Position Paper","volume":"27","author":"Champlat","year":"2016","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.2090","article-title":"Pembrolizumab-Induced Sarcoid Granulomatous Panniculitis and Bullous Pemphigoid in a Single Patient","volume":"7","author":"Honigman","year":"2019","journal-title":"Clin Case Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13687","article-title":"Neutrophil-Predominant Bullous Pemphigoid Induced by Checkpoint Inhibitors: A Case Series","volume":"47","author":"Morris","year":"2020","journal-title":"J Cutan Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune Bullous Skin Disorders With Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and Management of Dermatologic Adverse Events to Agents Targeting the PD-1 Receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01934","article-title":"Checkpoint Inhibition may Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid","volume":"10","author":"Sadik","year":"2019","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220946370","article-title":"Bullous Pemphigoid in Elderly Woman Affected by Non-Small Cell Lung Cancer Treated With Pembrolizumab: A Case Report and Review of Literature","volume":"27","author":"Cosimati","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13984","article-title":"A Review of Bullous Pemphigoid Associated With PD-1 and PD-L1 Inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.731774\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T10:17:59Z","timestamp":1631614679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.731774\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":13,"alternative-id":["10.3389\/fimmu.2021.731774"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.731774","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"article-number":"731774"}}